Students in our Counseling Psychology program graduate well-prepared for a successful career as professional therapists. The program focuses on teaching students a relational and systemic model for ...
Sanofi has bolstered the case for its oral BTK inhibitor tolebrutinib as a treatment for multiple sclerosis (MS), due to be filed for approval in the latter half of this year, with new data in a ...
Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS). The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback